8-KEarnings & ResultsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Financial Results (Jul 19, 2007)

Filed July 19, 2007For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) filed a Form 8-K on July 19, 2007, to report its financial results for the quarter ended June 30, 2007. The filing primarily serves to attach a press release detailing these results, which is crucial for investors seeking to understand the company's recent performance and financial condition. Investors should note that the company presents both Generally Accepted Accounting Principles (GAAP) and non-GAAP financial measures, with management believing the non-GAAP figures offer a more useful perspective on operations by excluding stock-based compensation expenses and related impacts on dilutive securities. This approach is standard practice for many companies, but investors should always review the GAAP figures alongside non-GAAP metrics for a complete financial picture. The press release, incorporated by reference as an exhibit, would contain the specific financial figures, such as revenue, net income, and earnings per share, for the reported quarter. While the 8-K itself doesn't list these numbers, it signifies that Gilead is providing updated financial information to the market. The company's Chief Operating Officer and Chief Financial Officer, John F. Milligan, signed the report, underscoring the importance of these financial disclosures.

Key Highlights

  • 1Gilead Sciences, Inc. (GILD) filed an 8-K on July 19, 2007, reporting its Q2 2007 financial results.
  • 2The primary purpose of the filing is to include a press release announcing the financial results for the quarter ended June 30, 2007.
  • 3The company provides both GAAP and non-GAAP financial measures in its results.
  • 4Non-GAAP measures exclude stock-based compensation expense and related methodology for dilutive securities, which management finds useful for internal planning.
  • 5Investors are advised to consider non-GAAP information alongside GAAP financial statements for a comprehensive understanding.
  • 6The filing is signed by John F. Milligan, COO and CFO, highlighting the financial nature of the report.
  • 7The press release (Exhibit 99.1) contains the detailed financial results for the quarter.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Gilead Sciences' financial results for the fiscal quarter ended June 30, 2007, by attaching the press release that announces these results.

Yes, Gilead presents non-GAAP financial measures, such as non-GAAP net income and earnings per diluted share. Management believes these measures are useful for investors because they exclude the impact of stock-based compensation expense and the related methodology for deriving dilutive securities, providing a perspective they use internally for operating, budgeting, and financial planning.

The specific financial details for the quarter ended June 30, 2007, are contained within the press release issued by Gilead Sciences on July 19, 2007, which is filed as Exhibit 99.1 to this Form 8-K.

No, investors should not rely solely on non-GAAP financial information. The filing states that non-GAAP information is not prepared under comprehensive accounting rules and should only be used to supplement an understanding of the company's operating results as reported under GAAP. It is important to review both GAAP and non-GAAP figures for a complete picture.